Veradermics Inc (MANE) is not a good buy for a beginner, long-term investor at this time. The lack of positive financial performance, absence of trading trends, no news catalysts, and no proprietary trading signals indicate limited growth or momentum opportunities. Additionally, the company's financials show no growth, and there is no valuation data or analyst insights to support a buy decision.

Technical Analysis

No stock trend data is available for technical analysis. The market is currently pre-market with a price of $43.73, and the S&P 500 is down 0.11%.

Positive Catalysts

NULL identified. No news, trading trends, or significant signals are present.

Neutral/Negative Catalysts

No valuation data or analyst ratings are available. Hedge funds and insiders are neutral, with no significant trading trends.

Financial Performance

In 2024/Q4, revenue, net income, and EPS showed no growth (0.00% YoY). Net income remains negative at -$5.66M, and EPS is -1.37. Gross margin is 0.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

0 Analyst Rating

Wall Street analysts forecast MANE stock price to rise

0 Buy

0 Hold

0 Sell

Current: 45.850

Low

Averages

High

Current: 45.850

Low

Averages

High

Jefferies

initiated

$75

AI Analysis

2026-03-02

New

Reason

Jefferies

Price Target

$75

AI Analysis

2026-03-02

New

initiated

Reason

Jefferies initiated coverage of Veradermics with a Buy rating and $75 price target. The firm thinks the company's Phase 3 study has a high likelihood of success. The company's VDPHL01 extended release enables sustained plasma concentrations, the analyst tells investors in a research note.

Citi

NULL

Buy

initiated

$85

2026-03-02

New

Reason

Citi

Price Target

$85

2026-03-02

New

initiated

NULL

Buy

Reason

Citi initiated coverage of Veradermics with a Buy rating and $85 price target. The firm believes the company's VDPHL01 is positioned to become the first FDA-approved oral minoxidil for pattern hair loss. The drug will enter a $30B market with a major unmet need, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MANE

Unlock Now

MANE Should I Buy

MANE Should I Buy

Should You Buy Veradermics Inc (MANE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch